Evidence map›Paper›PMID 28724421›Full record

SynthesisBMC nephrology2017

Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis.

Bing Du, Ye Jia, Wenhua Zhou, Xu Min, Lining Miao, Wenpeng Cui

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. IgA Nephropathy: An Interesting Autoimmune Kidney Disease.The American journal of the medical sciences · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. The Emerging Role of Pathogenesis of IgA Nephropathy.Journal of clinical medicine · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bing DuDepartment of Cardiology, the Second Part of First Hospital, Jilin University, Changchun, 130031, China.
Ye JiaDepartment of Nephrology, Second Hospital, Jilin University, 218 Ziqiang Street, Changchun, Jilin, 130041, China.
Wenhua ZhouDepartment of Nephrology, Second Hospital, Jilin University, 218 Ziqiang Street, Changchun, Jilin, 130041, China.
Xu MinDepartment of Nephrology, Second Hospital, Jilin University, 218 Ziqiang Street, Changchun, Jilin, 130041, China.
Lining MiaoDepartment of Nephrology, Second Hospital, Jilin University, 218 Ziqiang Street, Changchun, Jilin, 130041, China.
Wenpeng CuiDepartment of Nephrology, Second Hospital, Jilin University, 218 Ziqiang Street, Changchun, Jilin, 130041, China. wenpengcui@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe application of mycophenolate mofetil (MMF) in treating patients with immunoglobulin A nephropathy (IgAN) remains uncertain. This update meta-analysis was performed to re-evaluate the therapeutic potential of MMF in IgAN.

methodsArticles were obtained by searching the electronic databases without language restriction. Randomized controlled trials studying the role of MMF in treating IgAN were collected. The quality of included studies was critically evaluated. Data analyses were performed by using RevMan 5.3 software.

resultsA total of 297 articles were screened and eight articles were finally included. Among the eight randomized controlled trials, five and three were high quality and low quality, respectively. Both fixed-effect and random-effect model were used. Pooled results by combining all the eight studies suggested that IgAN patients in MMF group had a higher remission rate than that in control group. Compared to placebo or corticosteroid monotherapy, MMF monotherapy exerted a higher remission rate and side effect rate in both main analysis and subgroup analysis by human race. Compared to corticosteroid plus other immunosuppressive agent therapy, corticosteroid plus MMF therapy had a higher remission rate, lower serum creatinine doubling rate, progression to end-stage renal disease rate and side effects rate. Subgroup analysis by therapeutic regimen further confirmed these results between corticosteroid plus MMF therapy and corticosteroid plus cyclophosphamide therapy. Funnel-plot displayed a symmetrical figure, indicating no publication bias existed.

conclusionsMMF has the potential in treatment of IgAN, especially for Asians. The evidence currently available shows that MMF monotherapy has a more efficacy but higher side effects when compared to placebo or corticosteroid monotherapy in treatment of Asians with IgAN. While MMF combined with corticosteroid regimen has a more efficacy and lower side effects when compared with corticosteroid plus cyclophosphamide regimen.

Indexed as

Antibiotics, AntitubercularAsian PeopleGastrointestinal DiseasesGlomerulonephritis, IGAHumansMycophenolic AcidRandomized Controlled Trials as TopicTreatment OutcomeAntibiotics, AntitubercularMycophenolic AcidImmunoglobulin a nephropathyMeta-analysisMycophenolate mofetil

Identifiers

PMID28724421
PMCPMC5517790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.